Glycosylation, the most abundant posttranslational modification, holds an unprecedented capacity for altering biological function. Our ability to harness glycosylation as a means to control biological systems is hampered by our inability to pinpoint the specific glycans and corresponding biosynthetic enzymes underlying a biological process. Herein we identify glycosylation enzymes acting as regulatory elements within a pathway using microRNA (miRNA) as a proxy. Leveraging the target network of the miRNA-200 family (miR-200f), regulators of epithelial-to-mesenchymal transition (EMT), we pinpoint genes encoding multiple promesenchymal glycosylation enzymes (glycogenes). We focus on three enzymes, beta-1,3-glucosyltransferase (B3GLCT), beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), and (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5), encoding glycans that are difficult to analyze by traditional methods. Silencing these glycogenes phenocopied the effect of miR-200f, inducing mesenchymal-to-epithelial transition. In addition, all three are up-regulated in TGF-β-induced EMT, suggesting tight integration within the EMT-signaling network. Our work indicates that miRNA can act as a relatively simple proxy to decrypt which glycogenes, including those encoding difficult-toanalyze structures (e.g., proteoglycans, glycolipids), are functionally important in a biological pathway, setting the stage for the rapid identification of glycosylation enzymes driving disease states.
glycan regulation | epithelial to mesenchymal transition | glycomics | miR-200 | TGF-beta G lycosylation is the most abundant posttranslational modification and regulates many biological processes essential to human health (1) , as evidenced by the >100 congenital disorders of glycosylation discovered to date (2) and the increasing number of glycosylation-related genes (glycogenes) identified in genomewide association studies in diseases ranging from heart disease (3) to schizophrenia (4) . However, pinpointing the glycans and their corresponding biosynthetic enzymes controlling specific biological events is a difficult endeavor for two main reasons: (i) glycans are an analytical challenge because of their structural complexity and the multiplicity of attachment sites, and (ii) glycan biosynthesis requires an intricate pathway with multiple, potentially redundant enzymes (e.g., glycosyltransferases) acting in tandem to create an epitope (5) . Decryption of this complex glycocode would unlock new avenues to control biological interactions.
MicroRNAs (miRNAs) are short noncoding RNAs that repress translation or initiate mRNA degradation through binding to the 3′ UTR of mRNAs (6) . Recent work by our laboratory has shown miRNAs are major regulators of the glycome (7) (8) (9) . To date 10 human glycogenes have been validated as miRNA targets in the literature (7, 8) . In several of these studies, inhibition of the glycogene recapitulates the biological effects of the miRNA (9-11). MiRNAs regulate networks of genes that work in concert to control biological processes (12, 13) . We hypothesize that miRNAs controlling a specific biological pathway can be used as a proxy to identify, through its target network, the functionally relevant glycogenes that modulate that biological process.
The cycling of cells between an epithelial (nonmotile) and mesenchymal (migratory) state (epithelial-to-mesenchymal transition, EMT, and mesenchymal-to-epithelial transition, MET) controls embryogenesis and wound healing. Proper orchestration of cell migration is critical during these events, and aberrant EMT is linked to various pathologies including birth defects, cancer metastasis, and fibrosis (14) . MiRNAs are known to play an important role in the regulation of EMT. The miR-200 family (miR-200f) is perhaps the best-characterized miRNA regulator of this process. Levels of mir-200f are high in epithelial cells, low in mesenchymal cells, and regulate expression of Zeb1 (zinc finger E-box binding homeobox 1), a transcription factor that represses E-cadherin (15) (16) (17) . MiR-200f is regulated by TGF-β, an inducer of EMT (16, 17) .
In this work, we leverage the glycogene target network of miR200f to identify glycosylation enzymes controlling EMT (16, 17) . We examine eight glycogenes within the predicted network and validate seven of the eight as targets of miR-200f. We then focus on three genes encoding the difficult-to-study glycans beta-1,3-glucosyltransferase (B3GLCT), beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), and (alpha-N-acetyl-neuraminyl-2,3-betagalactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) and show that, as predicted by the network, they act as regulators of the EMT pathway. Overall, our work provides evidence that miRNA networks can be used to identify key glycosylation enzymes within a biological process, suggesting that miRNA may be used as a proxy to crack the functional glycocode.
Significance
Carbohydrates hold an unprecedented capacity for altering biological function, but determining which glycans and underlying enzymes are crucial for a specific biological pathway is a major impediment to our understanding of this posttranslational modification. Here we demonstrate that the mRNA target networks of microRNA (miRNA), small noncoding RNA, identify glycosylation enzymes acting as regulatory elements within a biological pathway. Leveraging the miRNA-200 family (miR-200f), regulators of epithelial-to-mesenchymal transition (EMT), we identify multiple promesenchymal glycosylation enzymes. Silencing miR-200f-targeted glycogenes phenocopies the effect of miR-200f, inducing mesenchymal-to-epithelial transition. These enzymes are upregulated in TGF-β-induced EMT, suggesting tight integration within the signaling network. Our work indicates that miRNA networks can be used to identify crucial glycosylation enzymes driving disease states.
Results
MiR-200f Targets a Broad Network of Glycogenes. To identify miR200f targets, we created a map of miR-200f-glycogene interactions based on conserved and nonconserved miRNA site predictions from miRanda ( Fig. 1A) (7) . We considered only glycogene targets with an mirSVR score of −0.1 or less, enhancing the probability of target down-regulation upon miRNA binding (18) . We further simplified our network by focusing on glycosyltransferases. In constructing our network we included the five known members of The two groups differ from each other within their seed regions by only one nucleotide (16) . In line with these differences, we observed three clusters of predicted targets, those exclusive to miR-141/200a, those exclusive to miR-200b/200c/429, and those predicted to be targeted by both sets of miRNAs. The predicted glycogene targets were distributed approximately evenly between N-linked, O-linked (i.e., αGalNAc-Ser/Thr), noncanonical O-linked, and glycolipid biosynthetic pathways with some glycosaminoglycan and terminal modifications also represented, indicating that this family controls a diverse range of glycans (Table S1) .
We selected eight targets within the miRNA-glycogene network for validation using a 3′-UTR-luciferase reporter assay (Fig. 1) . MiRNA mimics that repressed luciferase expression by ≥25% [log 2 (mimic/scramble) = −0.42; red line in Fig. 1B] were considered significant inhibitors of the glycogene. miRNA-binding sites were validated by mutagenesis of the seed-binding regions of the 3′-UTR-luciferase constructs (Fig. 1B and Table S2 ). MiRNA mimics of miR-141, -200c, and -429 gave results similar to those of other members within their group (Fig. S1) . Of the eight targets tested, only MGAT2 was not targeted by miR-200f. In addition, two genes predicted to be targets of all family members, B3GLCT and ST3GAL5, were targeted only by miR-200b/200c/429 (Fig. 1B  and Fig. S1 ). Overall, our data confirmed multiple miR-200f-glycogene interactions and identified clear differences in the ability of the two distinct groups of miR-200f members to target glycogenes.
MiR-200f
Regulates the Glycome in MDA-MB-231 Cells Undergoing MET. MiR-200f levels are high in epithelial cells, which express high levels of E-cadherin, form tight junctions, and have low motility. Conversely, miR-200f is low in mesenchymal cells, which lose cell-cell contacts and are characterized by low levels of E-cadherin and high motility (16, 17) . The highly metastatic breast cancer cell line MDA-MB-231 is considered mesenchymal and is commonly used to examine MET (12, 17) . MiR-200f is known to cause MET within this cell line (12, 17, 19) . Previous reports have not distinguished clearly between the effects of the two miR-200f groups, often using combinations of miRNAs from both sets. Our luciferase data suggest that the two miR-200f groups have disparate effects on the glycome. Transfection of MDA-MB-231 cells with either miR200a or -200b mimics induced changes in morphology consistent with MET, but these changes were more apparent in miR-200b-treated cells ( Fig. 2A ). This observation was confirmed by examination of MET markers. The expected increase in E-cadherin and loss of vimentin and ZEB1 expression were observed in both miRNA treatments but were more pronounced for cells treated with miR-200b mimics ( (Table S3 ). Overall, we found a larger number of predicted glycogenes altered in the miR200b-treated samples (miR-200a: 8/33; miR-200b: 15/33), indicating that miR-200b has a more profound effect on the glycome in this system. In examining the data, we noticed that none of the glycogenes exclusive to the N-linked pathway was affected significantly by either miRNA. Lectin microarray analysis of miR-200a-and -200b-treated cells showed no changes in N-linked-specific lectin binding (Fig. S3 ), in line with our mRNA expression (Table S3 ) and luciferase (Fig. 1B) data. In general, few changes were observed on our lectin microarrays, which have limited analytical capacity for glycolipids, glycosaminoglycans, and noncanonical O-links (i.e., the majority of miR-200f targets). In light of these data, we focused our attention on three specific glycogenes in the miR-200b network from the glycolipid and noncanonical O-linked pathways: B3GLCT, which catalyzes the addition of a glucose to O-fucosylated serines and threonines; ST3GAL5, a sialyltransferase that modifies the figure. (B) Graphical representation of luciferase data. Luciferase-3′-UTR reporter constructs were cotransfected with miRNA or scramble mimics (60 nM) in HEK 293T/17 cells. Luciferase signal was assayed 24 h posttransfection. The graphs display average log 2 (mimic/ scramble). n = 3 biological replicates; *P < 0.005, t test. For wild-type constructs (black bars) displaying a ≥25% decrease (red line), mutants of the appropriate binding region were tested (gray bars; see Table S2 ). Fig. S1 shows the effect of all five miR-200f members on select constructs. Error bars represent the SD.
glycolipid lactosylceramide to form GM3; and ST6GALNAC5, which transfers a sialic acid to the N-acetylgalactosamine on the glycolipid GM1b to form GD1α (Fig. 2 D-F, respectively) (20) .
Our candidate genes were chosen for three reasons: (i) all three displayed >40% down-regulation by miR-200b in our luciferase assays (Fig. 1B) ; (ii) all three were associated with human disease (3, (21) (22) (23) (24) ; (iii) all three glycogenes showed significant changes in mRNA expression levels in miR-200b-treated MDA-MB-231 cells undergoing miRNA-induced MET (P ≤ 0.01) (Table S3) . Unlike B3GLCT and ST3GAL5, the expression of ST6GALNAC5 mRNA increased in the miR-200b-treated samples (Fig. 2 G-I ). This finding is in contrast to both the luciferase data for the ST6GALNAC5 3′-UTR construct (Fig. 1B) and protein expression levels, which were repressed for all three enzymes by miR-200b (Fig. 2 J-L) . It is common for miRNA to repress translation in the absence of an mRNA degradation effect (6), as is observed here for ST6-GALNAC5. To determine whether glycans synthesized by these glycogenes were down-regulated by miR-200b, we used fluorescence microscopy to examine the levels of GM3, the glycolipid product of ST3GAL5 (Fig. 2E) , in response to miR-200b treatment ( (Fig. 3A) . We evaluated E-cadherin expression in B3GLCT-and ST3GAL5-silenced cells at day 5 and, because of slower growth rates, in ST6GALNAC5-silenced cells at day 10 ( Fig. 3 and Fig. S4 ). Gene silencing resulted in increased expression of E-cadherin at both the protein and transcript levels, in line with the observed morphological changes. ZEB1 levels also were increased in all three knockdowns, indicating that the increase in E-cadherin is not caused by repression of this transcriptional regulator (Fig. S2B) .
MiR-200f regulates not only the morphology but also the migratory capacity of cells (12, 19) . Previous studies have shown that miR-200f expression in MDA-MB-231 cells inhibits the migration of this cell line in wound-healing assays (12, 19) . To test whether silencing B3GLCT, ST3GAL5, or ST6GALNAC5 mimics the effects of miR-200b on the migratory capacity of MDA-MB-231 cells, we performed in vitro scratch assays (25) . Migration was evaluated after 24 h, which is less than the doubling time of MDA-MB-231 cells (26) . As expected, transfection of MDA-MB-231 cells with miR-200b mimics inhibited gap closure in the scratch assay as compared with a scrambled control (46% of control, P = 0.01) (Fig. 4  A and B) . Silencing of B3GLCT, ST3GAL5, or ST6GALNAC5 recapitulated the inhibition of migration observed with miR-200b (P < 0.001 for B3GLCT and ST6GALNAC5; P = 0.02 for ST3GAL5) (Fig. 4 C and D) . The strongest effect was observed in the B3GLCT knockdown (20% of control). Migration was reduced to 38% of control in ST6GALNAC5-silenced cells and to 67% of control in ST3GAL5-silenced cells. Thus, silencing glycogenes targeted by miR-200b phenocopies the effects of the miRNA, suggesting that miR-200f regulates glycosylation enzymes that are important components of the biological pathways it controls.
TGF-β1 Induces Both EMT and Increased Protein Expression of B3GLCT, ST3GAL5, and ST6GALNAC5 in A549 Cells. We tested whether B3GLCT, ST3GAL5, and ST6GALNAC5 were involved in the more complex EMT networks induced by a natural stimulus of EMT, TGF-β1. TGF-β1 is a cytokine known to induce EMT, in part through upregulation of the transcription factor Zeb1, a repressor of both miR200f and E-cadherin (16, 27) . We examined the effects of TGF-β1 on A549 cells, a human nonsmall cell lung carcinoma line that has been used previously to study TGF-β1-induced EMT (28) . In brief, cells were treated with TGF-β1 (5 ng/mL) for 48 h. Changes in morphology consistent with EMT could be observed as soon as 24 h after treatment. By 48 h, the majority of cells displayed the spindleshaped morphology characteristic of a mesenchymal phenotype (Fig. 5A) . Analysis of E-cadherin, fibronectin (a mesenchymal marker), vimentin, and Zeb1 by qRT-PCR in these cells confirmed the induction of EMT (Fig. 5B) . We analyzed the expression of B3GLCT, ST3GAL5, and ST6GALNAC5 transcripts in these cells (Fig. 5C) . Because of the very low expression levels of the ST6GALNAC5 mRNA, we were not able to determine changes in this transcript by qRT-PCR. Both B3GLCT and ST3GAL5 showed significant increases in expression (3.5-fold and 1.5-fold, respectively) compared with untreated cells. We observed increases in protein expression levels consistent with the changes in glycogene mRNA (Fig. 5D) . By loading threefold more protein than was used in the Western blot analysis of B3GLCT and ST3GAL5, we were able to observe an increase in ST6GALNAC5 protein expression because of TGF-β1-induced EMT. Overall our results suggest that glycogenes targeted by miR-200b are promesenchymal genes that are part of the broader EMT-signaling network induced by TGF-β1.
Discussion
Glycosylation can impact many aspects of the cell, from cell adhesion to receptor clustering and activation (Fig. 6 ). For example, glycosylation of E-cadherin, fibronectin, and other EMTassociated glycoproteins governs their roles in adhesion and motility, altering their stability and protein-interaction networks (29) (30) (31) . A single glycosylation enzyme can regulate multiple components of a biological pathway, exerting a synergistic effect. Current approaches to identifying functionally relevant glycans are focused on glycan analysis to identify glycans that alter in disease and on glycogene profiling to identify changes in mRNA that correlate with disease states. These approaches have several limitations. (i) High-throughput analysis of glycans typically is qRT-PCR data are reported as the average of relative expression normalized to GAPDH. Error bars denote SD; *P < 0.005; t test; n = 3 biological replicates. (C) Relative abundance of mRNA encoding glycogenes B3GLCT and ST3GAL5 in the samples used in B. qRT-PCR data are reported as the average of relative expression normalized to GAPDH. Error bars denote SD; *P < 0.002; **P < 0.01; t test; n = 3 biological replicates. (D) Western blot data for samples used in B and C show a decrease in E-cadherin and a concomitant increase of B3GLCT, ST3GAL5, and ST6GALNAC5 protein levels. To visualize ST6GAL-NAC5, threefold-higher sample levels (60 μg protein) were evaluated. Representative data from the three biological replicates are shown.
not comprehensive (5). The great majority of studies on glycans in disease focus on only the N-linked glycome. Glycolipids, O-linked glycans, and glycosaminoglycans often are ignored because of difficulties in sample preparation and annotation in mass spectrometry and a lack of specific binding reagents. (ii) Glycogene transcripts often are at the limits of detection, where quantitation is inaccurate, complicating mRNA profiling (32, 33) . (iii) The multiple glycosylation enzymes with overlapping catalytic specificities present a challenge in mapping changes in glycan structure to changes in specific enzyme levels (34) . (iv) It is not clear that all changes in glycosylation correlating with a disease state or biological process are relevant. Some alterations may be bystanders of the expression of other functionally relevant glycans (35) . Identifying the parts of the glycocode that are meaningful in terms of biological function in a specific system is more complex than simply identifying changes in glycosylation.
In this work we demonstrate a previously undescribed strategy for decrypting the functional glycocode that leverages miRNA as a proxy for identifying glycosylation enzymes that are important for a specific biological process, EMT (Fig. 6) . By leveraging miR-200f target networks (Fig. 1) , we identified a set of relevant glycogenes from the cohort that biosynthesize glycans ignored in typical glycan analysis. MiR-200f strongly impacted glycogenes controlling glycolipid, glycosaminoglycan, and O-linked glycan biosynthesis (Table S3) , which comprise 65% of predicted targets (Table S1 ), rather than the N-linkedassociated glycogenes that are the focus of most research. Our miRNA strategy bypasses the analytical constraints attached to glycolipids, glycosaminoglycans, and O-linked glycans to identify specific glycosylation enzymes and, by extension, the epitopes they biosynthesize as modulators of the EMT pathway.
From the broader miR-200f network, we focused our studies on three targets: B3GLCT, ST6GALNAC5, and ST3GAL5, which biosynthesize noncanonical O-linked glycans and glycolipids (Fig. 2  D-F) . Knocking down any of these three glycogenes phenocopied the known effects of miR-200f, reversing the mesenchymal phenotype, increasing E-cadherin, and slowing cell migration. These effects were not mediated by the transcription factor Zeb1, indicating that these glycans affect protein expression and/or stabilization of E-cadherin independent of the transcriptional repressor. Induction of EMT by TGF-β1 increased the expression of all three glycosylation enzymes. This finding is in line with the known function of TGF-β, which inhibits mir-200f. Taken together, our data demonstrate that miR-200f controls glycosylation enzymes that are functionally relevant to EMT and that miRNA can be used as a proxy to place these enzymes into biological context.
Placing glycogenes into context within specific pathways using miRNA as a predictor may offer insight into the roles of glycosylation in human disease. MiR-200f is a regulatory component of the TGF-β EMT-signaling pathway, implying that B3GLCT, ST6GALNAC5, and ST3GAL5 also are components of that pathway. Increased levels of the glycolipid GM3, the product of ST3GAL5, have been shown to promote the dimerization and activation of TGF-β receptors (36) . However, B3GLCT and ST6GALNAC5 are not known to be involved in EMT. Mutations that compromise the enzymatic activity of B3GLCT, the β1,3-glucosyltranferase previously annotated as B3GALTL, are the underlying cause of Peter's Plus syndrome (21) , a congenital disorder characterized by malformation of the eye (Peter's anomaly), short stature, and craniofacial features commonly including cleft palate (37) . TGF-β-induced EMT plays a predominant role in both the formation of the eye (38) and the closure of the palate during embryonic development (39) , and recent work has implicated B3GLCT in the secretion of thrombospondin-1, a protein involved in TGF-β activation (40) . Taken together, this report and our data suggest that Peter's Plus is a TGF-β-related EMT-disruption syndrome, similar to other congenital disorders with TGF-β-related mechanisms (41) . Coronary artery disease (CAD) caused by activating mutations in ST6GALNAC5 (3) also may be related to TGF-β-induced EMT. CAD has been linked to higher TGF-β levels (42) and fibrosis, an EMT process (43) . Thus, higher ST6GALNAC5 activity may promote TGF-β signaling, causing CAD. If these rare genetic mutations do impact TGF-β networks, drugs that target TGF-β signaling potentially could help patients with these syndromes, effectively deorphanizing these diseases by placing them in the larger context of TGF-β-related disorders.
Identifying functionally relevant glycosylation enzymes opens new avenues for therapeutics for virtually any disease (1). Glycosylation enzymes are overlooked as druggable targets because of the difficulties in pinpointing the critical enzymes in a disease state (34, 35, 44) . However, glycans play a role in every major disease (1), and there are clinical examples of drugs targeting glycosylation enzymes [Zavesca in Gaucher's disease (44) , zanamivir (Relenza) and oseltamivir (Tamiflu) in influenza (35) , and migalastat in Fabry's disease (44) ], suggesting that glycosylation enzymes may provide fallow ground for drug development. Multiple biological pathways governed by different miRNA often are involved in disease processes. Our approach enables these miRNA networks to be leveraged to yield the most critical enzymes to target in a disease state. Taking advantage of this concept will require a better map of glycogene-miRNA interactions (8) . By using miRNA as a relatively simple proxy to decrypt which glycogenes, including encoding difficult-to-analyze structures (e.g., proteoglycans, glycolipids), are important in specific biological states, this work provides a decryption key for the functional glycocode.
Experimental Procedures
Glycogene Target Analysis of miR-200f. Identification and visualization of miR200f glycogene targets and construction of the regulatory network was performed as previously described (7) with the following exception: Only glycosyltransferases with an mirSVR score of −0.1 or less were considered (18) .
Luciferase Reporter Assay. Luciferase reporter assays were performed as previously described using pLightSwitch-MT vector constructs (SwitchGear Genomics) (8) . Plasmids containing glycogene 3′ UTRs were obtained from SwitchGear Genomics (B3GLCT) or were cloned from cDNA using standard methods. Dataset S1 shows the primers and sequenced 3′ UTRs.
Cell Culture and TGF-β1 Treatment. The MDA-MB-231 and A549 cell lines (Division of Cancer Treatment and Diagnosis Tumor Repository, National Cancer Institute) were grown in RPMI-1640 medium (Lonza) supplemented with 10% (vol/vol) FBS (Innovative Research) and 2 mM L-glutamine (Lonza) at 37°C in 5% CO 2 . For TGF-β1 treatment, A549 cells were was seeded at a density of 500,000 cells in a 10-cm dish; 24 h later the medium was replaced with reduced FBS (5%) growth medium supplemented with 5 ng/mL human recombinant TGF-β1 (R&D; 240-B-002) or vehicle, and cells were cultured for additional 48 h.
Transfection of miRNA Mimics in MDA-MB-231 Cells. MDA-MB-231 cells were seeded in six-well plates (80,000 cells per well), cultured for 24 h, and transfected with miRNA mimics (50 nM) using Lipofectamine 2000 (Life Technologies). Cells were transfected again 72 h after the initial treatment and 6-12 h later were split into 2 × 60 mm dishes. Samples were harvested for protein or RNA extraction on day 7 posttransfection. Western Blotting. Lysates from cells lysed in cold RIPA buffer supplemented with protease inhibitors were subjected to standard Western Blot protocols (8) . The primary antibodies were α-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; 1:10,000), α-E-cadherin (1:1,000), α-ST6GALNAC5 (1:1,000), and α-Vimentin (1:10,000) from Abcam and α-B3GLCT (B3GALTL, 1:1,000) and α-ST3GAL5 (1:1,000) from Novus Biologicals. Secondary antibodies [α-mouse-HRP (GAPDH) or α-rabbit-HRP (all others) (Bio-Rad)] were used at 1:5,000. Blots were developed using SuperSignal West Pico (Thermo Scientific).
RNA Extraction and Real-Time qPCR. Total RNA was extracted from samples as previously described (8) . Glycogene profiling summarized in Tables S3 and S4 was obtained by using RT 2 Profiler PCR Array Human Glycosylation (Qiagen) and Power SYBR Green (Life Technologies) using the manufacturers' protocols. Additional primers were designed using PrimerSelect or NCBI primer blast and were purchased from Integrated DNA Technologies (Dataset S1). All cycle threshold values (Ct) were obtained by using the LightCycler Roche 480 Second Derivative Max algorithm.
Gene Silencing. MISSION shRNA clones (Sigma Aldrich) were obtained as viral stocks from the shRNA Core at New York University Langone Medical Center. MDA-MB-231 cells were seeded at 80,000 cells per well in a six-well format and were transduced 24 h later with shRNA lentivectors (multiplicity of infection = 2) in medium containing 8 μg/mL Polybrene (Sigma Aldrich; see Dataset S1 for shRNA sequences). After 48 h, the medium was replaced with selection medium (1 μg/mL puromycin). Cells were harvested for protein and RNA extraction as described in the text. Scratch Assay. MDA-MB-231 cells were seeded at 80,000 cells per dish in 35-mm dishes. MiRNA treatment and gene silencing were performed as previously described. Confluent monolayers of cells were scratched on day 6 (miR-200f treatment) or day 5 (silencing) using a P200 tip, and the medium was replaced to remove floating cells. Images were acquired immediately after the scratch and 24 h later. Images were analyzed in ImageJ using the MiToBo plugin (www2.informatik. uni-halle.de/agprbio/mitobo/index.php/Main_Page) to quantify the wound area at time 0 h and 24 h. The percent of wound closure was calculated for a minimum of three regions per replicate (for one of the scramble-treated biological replicates only one region was imaged) and was averaged for three biological replicates.
